Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Retained Earnings (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Retained Earnings for 14 consecutive years, with -$1.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 572603.36% year-over-year to -$1.5 billion, compared with a TTM value of -$1.5 billion through Dec 2025, down 572603.36%, and an annual FY2025 reading of -$1.5 billion, down 572603.36% over the prior year.
  • Retained Earnings was -$1.5 billion for Q4 2025 at Fate Therapeutics, down from $153000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $268000.0 in Q4 2024 and bottomed at -$1.5 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$460.8 million, with a median of -$2.4 million recorded in 2022.
  • The sharpest move saw Retained Earnings plummeted 1059060.47% in 2022, then surged 100.02% in 2024.
  • Year by year, Retained Earnings stood at -$769.1 million in 2021, then skyrocketed by 99.76% to -$1.9 million in 2022, then crashed by 65257.71% to -$1.2 billion in 2023, then soared by 100.02% to $268000.0 in 2024, then crashed by 572603.36% to -$1.5 billion in 2025.
  • Business Quant data shows Retained Earnings for FATE at -$1.5 billion in Q4 2025, $153000.0 in Q3 2025, and $62000.0 in Q2 2025.